The overall objective of this research project is to optimize initial guideline-compliant diagnostics in AML diseases by developing a molecular genetic panel for simultaneous determination of disease-associated genetic aberrations. Key is the development of DNA- and RNA-based multiplex assays for initial AML diagnostics. The assays are intended to provide information for both prognostically and therapeutically highly relevant markers.
Technological basis of these assays is BIOTYPE’s Modaplex platform. A technology already validated with proof of concept will be further developed to meet the requirements of the multiplex degree in the special case of AML diagnostics.
Research partner:
